- Home/In The News/Blog/2014/August
6
August2014
category:
503b CompoundingCubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling certain lots of CUBICIN(R) (daptomycin for injection) to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer. Please click here for the list of affected CUBICIN lot information. The administration of a glass particulate, […]
read more5
August2014
category:
503b CompoundingSurvey: Drug Shortages May Weaken Cancer Care
Shortages of cancer drugs continue to take a toll on patient care, increasing drug errors and costs, and leading in some cases to the purchase of short-supply products from “gray-market” suppliers, according to results of a new survey of oncology practitioners. “We were expecting oncology drug shortages to be very common and we showed that, […]
read more